Apremilast – May 2022

• Brand names:
  • Otezla®
• Pharmaceutical Company:
  • Amgen Australia Pty Limited
• Condition/Indication: Severe chronic plaque psoriasis
• Meeting Date: May 2022
• Public Summary Document (PSD) May 2022 PBAC Meeting - (PDF 390KB)
• Public Summary Document (PSD) May 2022 PBAC Meeting - (Word 54KB)

Related Public Summary Document

• Apremilast – March 2022